Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region

European Journal of Haematology

Volumn 77, Issue 3, 2006, Pages 255-258

  Kitano, Kiyoshi ^a   Kobayashi, Hikaru ^b   Hanamura, Mayu ^a   Furuta, Kiyoshi ^a   Ueno, Mayumi ^b   Rokuhara, Akinori ^c   Tanaka, Eiji ^c   Umemura, Takeji ^c   Kiyosawa, Kendo ^c  

^a National Hospital Organization   (Japan)

^b NAGANO RED CROSS HOSPITAL   (Japan)

^c SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone marrow transplantation; Fulminant hepatitis; Hepatitis B virus

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHOTREXATE; POLYMYXIN B; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; ASPERGILLOSIS; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; COLITIS; CYTOMEGALOVIRUS INFECTION; FATIGUE; GENE MUTATION; HEPATIC COMA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAUNDICE; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FAILURE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RESPIRATORY FAILURE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VIRUS REACTIVATION; VIRUS REPLICATION;

ACUTE DISEASE; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; GENES, VIRAL; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; MALE; MUTATION; PROMOTER REGIONS (GENETICS); TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION;

EID: 33746335161     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00678.x     Document Type: Article

References (20)

1. DHÉDIN N, DOUVIN C, KUENTZ M, et al. Reverse seroconversion of hepatitis B after allogenic bone marrow transplantation. Transplantation 1988;66:616-619.
2. LIANG R, LAU GK, KWONG YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis carriers: a review of the problem. J Clin Oncol 1999;17:394-398.
3. YEO W, JOHNSON PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220.
4. WEBSTER A, BRENNER MK, PRENTRIC HG, GRIFFITHS PD. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 1989;4:207-208.
5. IWAI K, TASHIMA M, ITOH M, et al. Fulminant hepatitis B following bone marrow transplantation in an HBsAg-negative, HBsAb-positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow Transplant 2000;25:105-108.
6. SAKAMAKI H, SATO Y, MORI SI, et al. Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation. Int J Hematol 2001;74:342-346.
7. HUI C, LIE A, AU W, et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005;106:464-469.
8. OMATA M, EHATA T, YOKOSUKA O, HOSODA K, OHNO M. Mutations in the precore region of hepatitis B DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991;324:1699-1704.
9. LIANG TJ, HASEGAWA K, RIMON N, WANDS JR, BEN-PORATH E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-1709.
10. ROKUHARA A, TANAKA E, YAGI S, et al. De nove infection of hepatitis B virus in patients with orthotopic liver transplantation: analysis by determining complete sequence of the genome. J Med Virol 2000;62:471-478.
11. SATO S, SUZUKI K, AKAHANE Y, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Int Med 1995;122:241-248.
12. LING R, MUTIMER D, AHMED M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-713.
13. HUI C, SUN J, AU W, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005;42:813-819.
14. LAU GKK, LEMUR Y, FONG DYT, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic transplantation. Blood 2002;99:2324-2330.
15. GUNTHER S, PIWON N, IWANSKA A, SCHILLING R, MEISEL H, WILL H. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996;70:8318-8331.
16. BAUMERT TF, ROGERS SA, HASEGAWA K, LIANG TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996;98:2268-2276.
17. GEROLAMI R, HENRY M, BORENTAIN P, COLSON P, BOTTA D, TAMALET C. Fulminant hepatitis B associated with a specific insertion in the basal core promoter region of hepatitis B virus DNA after immunosuppressive treatment. Clin Infect Dis 2005;40:e24-e27.
18. HASHINO S, NOZAWA A, IZUMIYAMA K, et al. Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogenic bone marrow transplantation. Bone Marrow Transplant 2002;29:361-363.
19. OHNISHI M, KANDA Y, TAKEUCHI T, et al. Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. Transplantation 2002;73:812-815.
20. LAU GK, YIU HH, FONG DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterol 2004;126:1742-1749.